Director Alethia Young filed a Form 4 with the SEC on November 17, 2026, reporting the disposition of common stock and the cancellation of stock options in connection with the completed merger of Pacira BioSciences, Inc. into a wholly owned subsidiary of Viatris Inc.

Key Highlights

  • Shares disposed: Young disposed of 17,798 shares of common stock (including RSUs) on November 17, 2026, at $36.50 per share.
  • Merger trigger: The dispositions occurred pursuant to the Agreement and Plan of Merger, dated October 8, 2026, among Pacira BioSciences, Inc., Viatris Inc., and Peach Purchaser Sub Inc.
  • RSU treatment: According to the filing, each outstanding RSU was canceled and converted into the right to receive cash equal to the number of underlying shares multiplied by $36.50, subject to applicable tax withholdings.
  • Four stock options canceled: Options to purchase 12,179, 11,279, 10,891, and 30,967 shares of common stock were each disposed of at the effective time of the merger.
  • Option cash treatment: Each option was canceled and converted into the right to receive cash equal to the excess of $36.50 over the per-share exercise price, multiplied by the number of underlying shares, subject to applicable tax withholdings.
  • Post-transaction ownership: Following the reported transactions, Young's directly held common stock and all four reported options reflect zero remaining beneficial ownership.

Pacira BioSciences Director Alethia Young: Merger-Related Share and Option Dispositions on November 17, 2026

Director Alethia Young reported the disposition of 17,798 shares of Pacira BioSciences common stock on November 17, 2026, at a price of $36.50 per share, according to the filing. The filing notes this figure includes restricted stock unit awards. The transaction was coded "D" (disposition) and is attributed to the consummation of the merger described in the Agreement and Plan of Merger dated October 8, 2026, by and among Pacira BioSciences, Inc. (NASDAQ:PCRX), Viatris Inc., and Peach Purchaser Sub Inc.

At the effective time of the merger on November 17, 2026, the filing states that each outstanding share of Pacira BioSciences common stock was converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest. Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira BioSciences continuing as the surviving corporation and a wholly owned subsidiary of Viatris Inc.

In addition to common stock, the filing reports the cancellation of four stock options held by Young. The options carried exercise prices of $28.68, $24.34, $23.42, and $29.80 per share, covering 12,179, 11,279, 10,891, and 30,967 shares of common stock, respectively. Each option was converted into the right to receive a cash amount equal to the product of the number of underlying shares and the excess of $36.50 over the applicable exercise price, subject to tax withholdings. The filing further notes that any option with an exercise price greater than or equal to $36.50 would have been canceled with no consideration payable. The form was signed by Kristen Williams as attorney-in-fact on November 17, 2026.

What Was Disclosed

Pacira BioSciences director Alethia Young disclosed the merger-related disposition of 17,798 shares of common stock at $36.50 per share and the cancellation of four stock options on November 17, 2026, in connection with the acquisition of Pacira BioSciences by Viatris Inc.